Cantel Medical (CMD) Tops Q2 EPS by 29c, Revenues Beat

Cantel Medical (NYSE: CMD) reported Q2 EPS of $0.79, $0.29 better than the analyst estimate of $0.50. Revenue for the quarter came in at $294 million versus the consensus estimate of $276.63 million.

George Fotiades, Chief Executive Officer, stated, "We remain very optimistic with elevated uptake for our infection prevention consumable products as enhanced infection prevention protocols become standard practice. The increased adoption and focus on our IP&C solutions drove greater demand for our recurring revenue consumables and new products, enabling us to outperform underlying procedure volume in both our Medical and Dental segments. This resulted in a margin profile that exceeded expectations, mainly driven by favorable mix and volume leverage coupled with our embedded operating discipline across all of our businesses."

For earnings history and earnings-related data on Cantel Medical (CMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c